Zoetis Inc. $ZTS Shares Acquired by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,946 shares of the company’s stock after purchasing an additional 734 shares during the period. TD Waterhouse Canada Inc.’s holdings in Zoetis were worth $2,697,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Scott & Selber Inc. boosted its holdings in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares in the last quarter. Secure Asset Management LLC lifted its position in shares of Zoetis by 2.9% during the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares during the last quarter. Moment Partners LLC boosted its stake in shares of Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after acquiring an additional 72 shares in the last quarter. CVA Family Office LLC boosted its stake in shares of Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after acquiring an additional 74 shares in the last quarter. Finally, Menard Financial Group LLC grew its holdings in shares of Zoetis by 3.8% in the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company’s stock worth $305,000 after acquiring an additional 75 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $122.06 on Friday. The stock has a market capitalization of $53.79 billion, a P/E ratio of 21.01, a P/E/G ratio of 2.31 and a beta of 0.90. The business has a 50-day moving average of $137.75 and a two-hundred day moving average of $150.17. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $181.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s payout ratio is currently 33.67%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ZTS shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Morgan Stanley decreased their target price on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, November 10th. UBS Group cut their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, JPMorgan Chase & Co. cut their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.